Larvol Delta - Assembly-Biosciences-Doses-First-Participant-in-Phase-1a-Clinical-Study-of-Oral-Entry-Inhibitor-Candidate-ABI6250-for-Hepatitis-Delta-Virus

ABI-6250 - Assembly Biosci

https://www.globenewswire.com/news-release/2025/02/26/3032858/16259/en/Assembly-Biosciences-Doses-First-Participant-in-Phase-1a-Clinical-Study-of-Oral-Entry-Inhibitor-Candidate-ABI-6250-for-Hepatitis-Delta-Virus.html

Feb 26, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next